Mobile

Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and nec...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001667-22

Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess whether overall survival time in subjects receiving cetuximab in combination with cisplatin or carboplatin + 5-FU is prolonged compared to subjects receiving cisplatin or carboplatin + 5-FU only, in the first-line treatment of recurrent and/or metastatic SCCHN.

Critère d'inclusion

  • Recurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)

Liens